Free Trial
NASDAQ:UTHR

United Therapeutics (UTHR) Stock Price, News & Analysis

United Therapeutics logo
$452.18 -1.10 (-0.24%)
As of 12:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About United Therapeutics Stock (NASDAQ:UTHR)

Advanced

Key Stats

Today's Range
$449.51
$456.97
50-Day Range
$274.70
$453.28
52-Week Range
$266.98
$456.97
Volume
170,865 shs
Average Volume
592,998 shs
Market Capitalization
$20.40 billion
P/E Ratio
17.63
Dividend Yield
N/A
Price Target
$449.57
Consensus Rating
Moderate Buy

Company Overview

United Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

UTHR MarketRank™: 

United Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 134th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for United Therapeutics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    United Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about United Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for United Therapeutics are expected to grow by 12.30% in the coming year, from $24.48 to $27.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of United Therapeutics is 17.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.63.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of United Therapeutics is 17.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.64.

  • Price to Earnings Growth Ratio

    United Therapeutics has a PEG Ratio of 6.91. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    United Therapeutics has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about United Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.35% of the float of United Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    United Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in United Therapeutics has recently increased by 2.96%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    United Therapeutics does not currently pay a dividend.

  • Dividend Growth

    United Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.35% of the float of United Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    United Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in United Therapeutics has recently increased by 2.96%, indicating that investor sentiment is decreasing.
  • News Sentiment

    United Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for United Therapeutics this week, compared to 21 articles on an average week.
  • Search Interest

    Only 3 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,152,242.00 in company stock.

  • Percentage Held by Insiders

    10.30% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about United Therapeutics' insider trading history.
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UTHR Stock News Headlines

United Therapeutics (NASDAQ:UTHR) CEO Sells $1,798,760.00 in Stock
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
See More Headlines

UTHR Stock Analysis - Frequently Asked Questions

United Therapeutics' stock was trading at $352.84 at the beginning of 2025. Since then, UTHR stock has increased by 28.3% and is now trading at $452.6060.

United Therapeutics Corporation (NASDAQ:UTHR) issued its earnings results on Wednesday, July, 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by $0.39. United Therapeutics's revenue was up 11.7% on a year-over-year basis.
Read the conference call transcript
.

United Therapeutics' top institutional shareholders include New England Research & Management Inc. (0.01%), Moody National Bank Trust Division (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Paul A Mahon, Richard Giltner, Tommy G Thompson, James Edgemond, Louis W Sullivan, Judy D Olian, Nilda Mesa, Christopher Causey, Raymond Dwek, Jan Malcolm, Martine A Rothblatt, Michael Benkowitz and Christopher Patusky.
View institutional ownership trends
.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/30/2025
Today
10/06/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UTHR
CIK
1082554
Employees
1,305
Year Founded
1996

Price Target and Rating

High Price Target
$580.00
Low Price Target
$302.00
Potential Upside/Downside
-0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$25.62
Trailing P/E Ratio
17.69
Forward P/E Ratio
18.52
P/E Growth
6.91
Net Income
$1.20 billion
Net Margins
40.36%
Pretax Margin
52.54%
Return on Equity
18.73%
Return on Assets
16.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.26
Quick Ratio
6.94

Sales & Book Value

Annual Sales
$2.88 billion
Price / Sales
7.11
Cash Flow
$28.40 per share
Price / Cash Flow
15.96
Book Value
$144.34 per share
Price / Book
3.14

Miscellaneous

Outstanding Shares
45,110,000
Free Float
40,461,000
Market Cap
$20.45 billion
Optionable
Optionable
Beta
0.66

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:UTHR) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners